Keywords: rifampicine, improves, compliance, says, trial, swiss, drug
Rifampicine improves compliance says trial
Article | 20 October 2008
Swiss drug major Novartis' generics division Sandoz' Rifampicine (rifampin) four-month regimen increases compliance in latent tuberculosis patients when compared to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
